Taikang, China
Taikang, China

Time filter

Source Type

Sima L.,China Japan Friendship Hospital | Fang W.X.,Peking University | Wu X.M.,Chinese Academy | Li F.,Chinese PLA General Hospital
Journal of Clinical Pharmacy and Therapeutics | Year: 2012

What is known and Objective: Bone-cancer pain is a common and refractory cancer pain. Opioids, on their own, do not control this type of pain well enough, and co-analgesics are necessary. Methods: Patients with bone metastasis-related pain at Numeric Rating Scale ≥4 were enrolled to this randomized placebo-controlled trial. They had also received morphine or transdermal fentanyl patches for at least 1 week. During the 3-day efficacy phase, patients received placebo or 1-3 tablets of oxycodone/paracetamol (5/325 mg), four times daily for 3 days. All patients kept a daily pain diary. The primary endpoint was the Pain Intensity Difference (PID). Secondary endpoints were cases of breakthrough pain and rescue morphine consumption. Additional analyses included the Short Form-6 Dimensions (SF-6D) quality-of-life scale and a general impression (GI) of patient satisfaction with treatment at the end of the phase. Results and Discussion: Of the 246 patients in the intent-to-treat set, 89·4% completed the 3-day efficacy phase. PIDs were 0·9 and 0·3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0·001), and 1·5 and 0·3 respectively on day 3 (P < 0·001). Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0·001). The SF-6D score decreased to 21·2 ± 2·5 in the oxycodone/paracetamol group at the end of the phase (P = 0·001). In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent. What is new and Conclusion: Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing. © 2011 Blackwell Publishing Ltd.

October 31, 2016 -Chinese Academy of Sciences and Clarivate Analytics today released "Research Fronts 2016", an annual report identifying prominent areas of scientific research over the past year. This is the third collaborative report from these two organizations. The joint paper identifies 180 key research fronts including 100 hot and 80 emerging fronts, based on a comprehensive analysis of scientific literature citations. The analysis generated 12,188 research fronts in the Essential Science Indicators (ESI) database from 2009 until 2015. Research fronts are specialties discovered when scientists cite one another's work, reflecting a specific commonality in the research, which can be experimental data, a concept or hypothesis or even a method. Working in collaboration with the Chinese Academy of Sciences, Clarivate bibliometric experts utilized the ESI database, a web-based research analytics platform and a unique compilation of science performance metrics and trend data based on scholarly paper publication counts and citation data from the Web of ScienceTM. Once identified, the research fronts built on recently published "core" or foundational journal articles. The 2016 report also features an analysis of the current and potential performance of six leading countries in the 180 research fronts -- USA, China, the UK, Germany, France and Japan. Analysts at the the Institutes of Science and Development and the National Science Library of the Chinese Academy of Sciences also analyzed the 180 research fronts provided by Clarivate in great depth and interpreted it to highlight 28 research fronts of particular interest. Read the full report: "Research Fronts 2016." Learn more about Essential Science IndicatorsSM, InCites™ and Web of Science. The Chinese Academy of Sciences is the linchpin of China's drive to explore and harness high technology and the natural sciences for the benefit of China and the world. Comprising a comprehensive research and development network, a merit-based learned society and a system of higher education, CAS brings together scientists and engineers from China and around the world to address both theoretical and applied problems using world-class scientific and management approaches. Since its founding, CAS has fulfilled multiple roles -- as a national team and a locomotive driving national technological innovation, a pioneer in supporting nationwide S&T development, a think tank delivering S&T advice and a community for training young S&T talent. For more information, please visit http://english. . ClarivateTM Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas, faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we've been assisting our customers for over 60 years. Now as an independent company with over 4,000 employees, operating in more than 100 countries around the world, we remain expert, objective and agile. For more information, please visit us at Clarivate.com.

Bernabei R.,University of Rome Tor Vergata | Belli P.,University of Rome Tor Vergata | Cappella F.,University of Rome La Sapienza | Cappella F.,National Institute of Nuclear Physics, Italy | And 19 more authors.
European Physical Journal C | Year: 2013

The results obtained with the total exposure of 1.04 ton × yr collected by DAMA/LIBRA-phase1 deep underground at the Gran Sasso National Laboratory (LNGS) of the I.N.F.N. during 7 annual cycles (i.e. adding a further 0.17 ton × yr exposure) are presented. The DAMA/LIBRA-phase1 data give evidence for the presence of Dark Matter (DM) particles in the galactic halo, on the basis of the exploited model independent DM annual modulation signature by using highly radio-pure NaI(Tl) target, at 7.5σ C.L. Including also the first generation DAMA/NaI experiment (cumulative exposure 1.33 ton × yr, corresponding to 14 annual cycles), the C.L. is 9.3σ and the modulation amplitude of the single-hit events in the (2-6) keV energy interval is: (0.0112±0.0012) cpd/kg/keV; the measured phase is (144±7) days and the measured period is (0.998±0.002) yr, values well in agreement with those expected for DM particles. No systematic or side reaction able to mimic the exploited DM signature has been found or suggested by anyone over more than a decade. © 2013 The Author(s).

Bernabei R.,University of Rome Tor Vergata | Belli P.,University of Rome Tor Vergata | Cappella F.,University of Rome La Sapienza | Cappella F.,National Institute of Nuclear Physics, Italy | And 16 more authors.
European Physical Journal C | Year: 2010

DAMA/LIBRA is running at the Gran Sasso National Laboratory of the I. N. F. N. Here the results obtained with a further exposure of 0.34 ton × yr are presented. They refer to two further annual cycles collected one before and one after the first DAMA/LIBRA upgrade occurred on September/October 2008. The cumulative exposure with those previously released by the former DAMA/NaI and by DAMA/LIBRA is now 1. 17 ton × yr, corresponding to 13 annual cycles. The data further confirm the previous positive results obtained investigating the presence of Dark Matter (DM) particles in the galactic halo by means of the model independent Dark Matter annual modulation signature; the confidence level is now 8.9 σ for the cumulative exposure. In particular, with the cumulative exposure the modulation amplitude of the single-hit events in the (2-6) keV energy interval measured in NaI(Tl) target is (0.0116±0.0013) cpd/kg/keV; the measured phase is (146±7) days and the measured period is (0.999±0.002) yr, values well in agreement with those expected for the DM particles. © Springer-Verlag / Società Italiana di Fisica 2010.

Bernabei R.,University of Rome Tor Vergata | Belli P.,University of Rome Tor Vergata | Cappella F.,University of Rome La Sapienza | Cappella F.,National Institute of Nuclear Physics, Italy | And 14 more authors.
European Physical Journal C | Year: 2012

This paper gathers arguments and reasons why muons surviving the Gran Sasso mountain cannot mimic the Dark Matter annual modulation signature exploited by the DAMA/NaI and DAMA/LIBRA experiments. A number of these items have already been presented in individual papers. Further arguments have been addressed here in order to present a comprehensive collection and to enable a wider community to correctly approach this point. © 2012 The Author(s).

Bernabei R.,University of Rome Tor Vergata | Belli P.,University of Rome Tor Vergata | Bussolotti A.,University of Rome Tor Vergata | Cappella F.,University of Rome La Sapienza | And 21 more authors.
Journal of Instrumentation | Year: 2012

New dedicated high quantum efficiency (Q.E.) photomultipliers (PMTs) have been produced by HAMAMATSU company, tested, selected and installed in the DAMA/LIBRA set-up at the Gran Sasso National Laboratory (LNGS) of the I.N.F.N.. In this paper the results obtained in the measurements of various features of these high Q.E. PMTs are reported, and some performances of DAMA/LIBRA in this new configuration are shown. © 2012 IOP Publishing Ltd and Sissa Medialab srl.

News Article | February 15, 2017
Site: motherboard.vice.com

Gene editing for the purpose of preventing disease is cool, but not for the purpose of creating enhanced humans, according to a new, groundbreaking report from the National Academies released Tuesday. For the first time, an interdisciplinary, international expert panel has advised that research of clinical applications of germline editing, or traits that can be inherited, using gene editing technology such as CRISPR-Cas9, could go ahead—if a number of criteria are met—paving the way for "designer babies," or at least, babies that have been engineered as embryos to not carry certain debilitating genetic diseases. The report, a massive, 250-plus-page work in the making since the December 2015 Gene Editing Summit, an international meeting hosted by the National Academies and well as members of both the Royal Society of the United Kingdom (where germline editing has been approved in the form of mitochondrial donation therapy) and the Chinese Academy (where human embryos have been experimented on with CRISPR). The report aims to develop international norms on gene editing and begin to solidify global policy about using this technology between leading countries. The consensus report is essentially a gentlemen's agreement, for lack of a better term. Besides looking at the ethical and legal frameworks for therapeutic gene editing, the report also pointedly engages with the concept of enhancement, a tricky issue that is a distinct goal of the transhumanist movement, and which was a huge point of debate at the summit that inspired the report. However, the report's authors have made it abundantly clear that genome editing is not to be used for the purposes of "enhancement" at all, under any circumstances, and that if using gene editing for anything beyond treatment of diseases were to creep in behind clinical, therapeutic uses of technology like CRISPR, it would not even be worth using. R. Alta Charo, a leading American bioethicist and the co-chair of the report, insisted during the report's release panel today that genome editing, both somatic (non-heritable changes to genes) and germline (changes that are heritable) should be used for the treatment and prevention of disease and disability only. The general public has shown a continued concern about the idea of "designer babies," and although germline editing could absolutely produce children that were cured of certain genetic diseases, like sickle-cell anemia, for example, designing babies based on height, hair, or eye color, is still unethical, according to the report. "We are not talking about germline editing for so-called enhancements," said Charo, reiterating that the technology is to be used for "serious disease and conditions, not for enhancement" and that if conditions cannot be met, "it is not permissible to begin these trials despite the fact that some families would benefit." Charo noted that the report lists a series of "very strict, very stringent criteria and conditions that must be met before any clinical trial could be considered" for germline or heritable changes. She pointed out that we are "not even close to the amount of research we need for to move forward with this technique." In fact, even in the US, clinical research of germline editing cannot yet go ahead, because an FDA statute prohibits research that produces heritable changes in an embryo. Until that law is allowed to expire, the report notes, germline editing will still be off the table in the US. However, it's clear that the enhancement debate won't go away anytime soon. The report does mention the emergence of "academic transhumanism" in the gene editing debate, and in the enhancement chapter reiterates a number of the traditional arguments against the biolibertatian, and transhumanist positions, including: the slippery slope into an "unnatural" society where some members of the species are edited and others aren't, the issue of eugenics, and the philosophical debate that the parent-child relationship would be altered. It also points out that the arguments in favor of enhancement for one's own children, based on either morality or personal liberty, are not at present supported by the US justice system, which the report states "would need a reproductive rights framework to be stretched to its limits in order to encompass the right to enhance or diminish traits." While the report's authors do briefly consider the DIY bio movement, a member of the panel today almost rejected out of hand that biohackers might take enhancements into their own garage "clinics," as it were. "One has to distinguish DIY science going on particularly as a hobby that can be applied to bacteria or simple organisms. It cannot be applied to clinical applications, that's a long way off," said Richard Hynes, a cancer researcher at MIT and co-chair of the report. "The delivery of any genome editing product into a patient is a much more challenging issue… And would require more than just DIY activities. It would require sophisticated clinics." That said, Stat makes the excellent point that stem cell clinics provide a similar, unregulated clinical experience. The report's authors do urge clarity on these matters, but until there is a clear and concise ban on enhancing oneself in one's own garage, the biohackers are on their own. It would not be difficult to imagine a self-edited transhumanist happily living in this legal and ethical grey area.

Chinese Academy | Date: 2010-09-26

An ionic liquid solvent and gas purification method using the same are provided. The ionic liquid solvent consists of a main absorbent, a regulator for the main absorbent, an auxiliary absorbent, an activator, an antioxidant and water. The ionic liquid involves a low synthetic cost, low viscosity and high absorption capacity, and can be easily regenerated and recycled. The method, compared with traditional processes, has advantages such as a greater absorption capability and lower operation cost.

The present invention provides a device system structure based on hybrid orientation SOI and channel stress and a preparation method thereof. According to the preparation method provided in the present invention, first, a (100)/(110) global hybrid orientation SOI structure is prepared; then, after epitaxially growing a relaxed silicon-germanium layer and strained silicon layer sequentially on the global hybrid orientation SOI structure, an (110) epitaxial pattern window is formed; then, after epitaxially growing a (110) silicon layer and a non-relaxed silicon-germanium layer at the (110) epitaxial pattern window, a surface of the patterned hybrid orientation SOI structure is planarized; then, an isolation structure for isolating devices is formed; and finally, a P-type high-voltage device structure is prepared in a (110) substrate portion, an N-type high-voltage device structure and/or low voltage device structures are prepared in the (100) substrate portion. In this manner, a carrier mobility is improved, Rdson of a high-voltage device is reduced, and performance of devices are improved, thereby facilitating further improvement of integration and reduction of power consumption.

The present invention provides an equivalent electrical model of a Silicon On Insulator (SOI) Field Effect Transistor (FET) of a body leading-out structure, and a modeling method thereof. The equivalent electrical model is formed by an internal FET and an external FET connected in parallel, where the SOI FET of a body leading-out structure is divided into a body leading-out part and a main body part, the internal FET represents a parasitic transistor of the body leading-out part, and the external FET represents a normal transistor of the main body part. The equivalent electrical model provided in the present invention completely includes the influence of parts of a physical structure of the SOIMOSFET device of a body leading-out structure, that is, the body leading-out part and the main body part, on the electrical properties, thereby improving a fitting effect of the model on the electrical properties of the device.

Loading Chinese Academy collaborators
Loading Chinese Academy collaborators